

CASE PC/4-31388B

CERTIFICATE OF FACSIMILE TRANSMISSION		
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being facsimile transmitted to the Patent and Trademark Office on the date shown below.		
<u>Amel Gehring</u> Type or print name	<u>Amel Gehring</u> Signature	<u>Oct 8 2004</u> Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

BHALAY ET AL.

Examiner: Taofiq A. Solola

APPLICATION NO: 10/644,328

FILED: AUGUST 20, 2003

FOR: 8-QUINOLINXANTHINE AND 8-ISOQUINOLINXANTHINE
DERIVATIVES AS PDE 5 INHIBITORS

RECEIVED

OCT 08 2004

OFFICE OF PETITIONS

MS: 313(c)

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION UNDER 37 CFR §1.313(c)(2) TO WITHDRAW APPLICATION FROM ISSUE

Sir:

Applicant respectfully petitions for the withdrawal from issuance of the above-identified patent application. Submitted herewith is a Request for Continued Examination of the above-identified application. Applicant is petitioning for the withdrawal from issue of the present application, and is filing a Request for Continued Examination, in order that a recently identified error in the publication number of reference WO 94/28904 listed in Form PTO-1449 was discovered. The correct publication number should be WO 94/28902 as indicated in the enclosed Supplemental Form PTO-1449.

Please charge the petition fee of \$130 pursuant to 37 CFR §1.17(h) to Deposit Account Number 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-2614

Gregory C. Houghton
Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: 10/8/04